COMPOSITION FOR PREVENTING OR TREATING PULMONARY DISEASES COMPRISING HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 1

• Main Authors: ZHOU, Dan, PARK, Bo Kyung, YUN, So Yoon, KIM, Dae Kyong, JANG, Ji Min, PIAO, Yong Wei
• Format: Patent
• Language: English; French
• Published: 12.08.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES; VINEGAR; WINE

Provided are a recombinant hyaluronan and proteoglycan link protein 1 (HAPLN1), and a composition for preventing or treating pulmonary diseases, the composition comprising at least one selected from the group consisting of HAPLN1 (hyaluronan and proteoglycan link protein 1) protein, a gene coding for the HAPLN 1 protein, and an effective agent for promoting the expression or activating the functions of HAPLN 1 protein or gene as an active ingredient. The recombinant HAPLN 1 according to the present disclosure may have superior effects of improving alveolar damage caused by aging or elastin reduction, and thus may effectively prevent or treat pulmonary diseases, such as chronic bronchitis, asthma, emphysema, and chronic obstructive pulmonary disease. L'invention concerne un acide hyaluronique recombinant et une protéine 1 de liaison protéoglycane (HAPLN1) ainsi qu'une composition pour prévenir ou traiter des maladies pulmonaires, la composition comprenant au moins un élément choisi dans le groupe constitué par HAPLN1 (acide hyaluronique et protéine 1 de liaison protéoglycane), un gène codant pour la protéine HAPLN 1 et un agent efficace pour favoriser l'expression ou activer les fonctions de la protéine ou du gène HAPLN 1 en tant que principe actif. Le HAPLN1 recombinant selon la présente invention peut avoir des effets supérieurs d'amélioration des dommages alvéolaires provoqués par le vieillissement ou la réduction de l'élastine et peut ainsi prévenir ou traiter efficacement des maladies pulmonaires, telles que la bronchite chronique, l'asthme, l'emphysème et la broncho-pneumopathie chronique obstructive.